Abstract
This study evaluated the in vitro activity of Ceftolozane/tazobactam (C/T) vs 10 comparator agents against Pseudomonas aeruginosa isolates obtained from clinical respiratory samples from pediatric patients with cystic fibrosis at three hospitals during 2015 to 2020. Antimicrobial susceptibility testing was performed using microbroth dilution technique with custom prepared Sensititre® MIC plates. MICs were determined via Sensititre Vizion® system and results were interpreted using current CLSI and EUCAST (2022) breakpoint criteria. C/T was the most potent agent as compared with other antipseudomonal drugs against 291 isolates with MIC50 = 1 μg/mL and MIC90 = 2 μg/mL with percent susceptibility as 95.2%. C/T remained active against majority of ß-lactam non-susceptible isolates; percent susceptibility ranging from 61.2% to 80% including 65.9% ceftazidime non-susceptible isolates. C/T had high activity against P. aeruginosa from 3 geographically diverse pediatric medical centers. Study results suggest that C/T may be used as a potential therapeutic option for treating pediatric patients with CF.
Original language | English (US) |
---|---|
Article number | 115904 |
Journal | Diagnostic Microbiology and Infectious Disease |
Volume | 105 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2023 |
Externally published | Yes |
Keywords
- Antimicrobial susceptibility
- MIC
- ceftolozane/tazobactam
- cystic fibrosis
- pediatric, Pseudomonas
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases